Le Lézard5h
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...
Los Angeles Times6h
Working to End the HIV Epidemic Through Innovation, Equity, Collaboration & Choice
Gilead is committed to designing trials to help understand how HIV treatment and prevention impact populations that have been ...
WCVB Channel 5 Boston14h
There are millions of sexually transmitted infections in the US every year, but new data shows the epidemic may be slowing
new study has indicated the United States is currently in the throes ... director of the CDC's National Center for HIV, Viral ...
Clinical trial shows immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Axios18h
Seattle biotech aims to cure hep B with breakthrough gene therapy
A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...
Science Daily21h
'Moonlighting' enzymes can lead to new cancer therapies
Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...
Sudden syphilis retreat in gay men is most likely tied to preventive antibiotic use
A new proven protocol in which doxycycline is used to prevent sexually transmitted infections — called doxyPEP — has been an ...